Intradermal immunotherapy for high-risk stage II melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your melanoma was at least 2.0 mm thick and has been removed within the last 4 weeks.
- You have not yet had a sentinel node biopsy or any additional surgery to the original melanoma site.
- Your doctors estimate your risk of the cancer spreading to a nearby lymph node is 44% or higher.
- You have not had prior immunotherapy (like ipilimumab or nivolumab) or targeted therapy for melanoma.
- You do not have an active autoimmune disease or a condition requiring strong immune-suppressing medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial studies an “immune cell” treatment for people with stage IV melanoma that is progressing despite prior care. It may help by boosting the body’s ability to recognize and attack melanoma cells.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.